Another point from today’s MNTA webcast: Craig Wheeler confirmed my speculation in #msg-33839413 vis-à-vis the royalty rate if there are multiple approved Lovenox generics. (Hopefully, this multiple-generic scenario does not come to pass, but it’s important to know the ramifications nonetheless.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”